ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to you

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Pavan	2. Surname (Last Name) Bhargava	3. Date 10-August-2017
4. Are you the corresponding author?	✓ Yes No	
5. Manuscript Title Metabolic alterations in multiple sclerc	osis and the impact of vitamin D supplementation	
6. Manuscript Identifying Number (if you k 95302-INS-CMED-RV-2	now it)	
Section 2. The Work Under C	onsideration for Publication	
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	eive payment or services from a third party (government g but not limited to grants, data monitoring board, study est? Yes I No	
Section 3. Relevant financial	activities outside the submitted work.	
of compensation) with entities as descr	in the table to indicate whether you have financial ibed in the instructions. Use one line for each entit port relationships that were present during the 3 est? Yes V No	y; add as many lines as you need by
Section 4.		
Intellectual Prope	rty Patents & Copyrights	
Do you have any patents, whether plan	ned, pending or issued, broadly relevant to the wo	ork? Yes 🖌 No



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disc

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Bhargava has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Kathryn	2. Surname (Last Name) Fitzgerald	3. Date 10-August-2017
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Name Pavan Bhargava
5. Manuscript Title Metabolic alterations in multiple sclerc	osis and the impact of vitan	nin D supplementation
6. Manuscript Identifying Number (if you k 95302-INS-CMED-RV-2	now it)	
Section 2. The Work Under C	onsideration for Public	cation
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .
Section 4. Intellectual Prope	rty Patents & Copyrig	ahts
Do you have any patents, whether plan	ć	



Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

Vo other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Fitzgerald has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Ellen	Mowry		3. Date 10-August-2017
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's N Pavan Bhargava	lame
5. Manuscript Title Metabolic alterations in multiple sc	lerosis and the impact of vita	min D supplementation	
5. Manuscript Identifying Number (if y 95302-INS-CMED-RV-2	ou know it)		

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?	Are there any	relevant	conflicts o	f interest?
---	---------------	----------	-------------	-------------

Yes 🖌 No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? \checkmark Yes \square No

If yes, please fill out the appropriate information below.

Name of Entity	Grant	Personal Fees	Non-Financial Support?	Other?	Comments	
Biogen	\checkmark					
Up To Date				\checkmark	Royalty fees	
Теvа			\checkmark			
Sun Pharma				\checkmark	Site Pl	
Biogen				\checkmark	Site Pl	
Sanofi-Genzyme	\checkmark					



Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

V No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Mowry reports grants from Biogen, other from Up To Date, non-financial support from Teva, other from Sun Pharma, other from Sin Pharma, other from Sin Pharma, other from Sin Pharma, other from Biogen, grants from Sanofi-Genzyme, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

✓ No



1. Given Name (First Name) Peter	2. Surname (Last Name) Calabresi	3. Date 10-August-2017
4. Are you the corresponding author?	Yes 🖌 No	Corresponding Author's Name Pavan Bhargava
5. Manuscript Title Metabolic alterations in multiple scler	osis and the impact of vitar	nin D supplementation
6. Manuscript Identifying Number (if you	know it)	
Section 2. The Work Under	Consideration for Public	cation
Did you or your institution at any time rec	eive payment or services from	a a third party (government, commercial, private foundation, etc.) f
Did you or your institution at any time rec any aspect of the submitted work (includir statistical analysis, etc.)?	eive payment or services from ng but not limited to grants, da	
Did you or your institution at any time rec any aspect of the submitted work (includir statistical analysis, etc.)?	eive payment or services from ng but not limited to grants, da	a a third party (government, commercial, private foundation, etc.) f
Did you or your institution at any time rec	eive payment or services from ng but not limited to grants, da	a a third party (government, commercial, private foundation, etc.) fo
Did you or your institution at any time rec any aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of inte	eive payment or services from ng but not limited to grants, da	a a third party (government, commercial, private foundation, etc.) f
Did you or your institution at any time rec any aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of inte	eive payment or services from ng but not limited to grants, da	a a third party (government, commercial, private foundation, etc.) f ata monitoring board, study design, manuscript preparation,
Did you or your institution at any time rec any aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of inte Section 3. Relevant financia Place a check in the appropriate boxes of compensation) with entities as desc	eive payment or services from ng but not limited to grants, da rest? Yes V No l activities outside the s in the table to indicate wh ribed in the instructions. Us	a a third party (government, commercial, private foundation, etc.) f ata monitoring board, study design, manuscript preparation, submitted work. wether you have financial relationships (regardless of amoun se one line for each entity; add as many lines as you need by
Did you or your institution at any time rec any aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of inte Section 3. Relevant financia Place a check in the appropriate boxes of compensation) with entities as desc	eive payment or services from ng but not limited to grants, da rest? Yes ✓ No I activities outside the s in the table to indicate wh ribed in the instructions. Us eport relationships that we	a a third party (government, commercial, private foundation, etc.) f ata monitoring board, study design, manuscript preparation, submitted work. ether you have financial relationships (regardless of amoun

Name of Entity	Grant	Fees?	Support?	Other?	Comments	
Medimmune	\checkmark					
Biogen	\checkmark					
Novartis	\checkmark					
Теvа	\checkmark					
Biogen		\checkmark				
Vertex		\checkmark				



Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes 🗸 No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

V No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Calabresi reports grants from Medimmune, grants from Biogen, grants from Novartis, grants from Teva, personal fees from Biogen, personal fees from Vertex, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

STROBE Statement-checklist of items that should be included in reports of observational studies

Please fill out the page numbers on this form and upload the file as a supplemental file when you submit your revision

Manuscript Number_

number ↓ (Or n/a if not applicable)

Indicate page

			applicable
	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control	
		selection. Give the rationale for the choice of cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) Cohort study-For matched studies, give matching criteria and number of exposed and unexposed	
		Case-control study-For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe	
measurement		comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen	
		and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) Cohort study-If applicable, explain how loss to follow-up was addressed	
		Case-control study-If applicable, explain how matching of cases and controls was addressed	
		Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility,	
		confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and	
-		potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	1
2 steering data	15		
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	
		Cross-sectional study-Report numbers of outcome events or summary measures	

			confidence interval). Make clear which confounders were adjusted for and why they were included					
			(b) Report category boundaries when continuous variables were categorized					
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period					
Other analyses		17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses					
Discussion								
Key results	18	Summa	arise key results with reference to study objectives					
Limitations	19	Discus	s limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and					
		magnit	tude of any potential bias					
Interpretation	20	Give a	cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar					
		studies	studies, and other relevant evidence					
Generalisability	21	Discus	Discuss the generalisability (external validity) of the study results					
Other informatio	Other information							
Funding	22	Give th	he source of funding and the role of the funders for the present study and, if applicable, for the original study on which					
		the pres	esent article is based					

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.